Table 1 Characteristics of the study population.

From: Prognostic prediction in soft-tissue sarcomas using deep learning and digital pathology of tumor and margin areas

Characteristics

All patients

(N = 308)

Training cohort

(n = 149)

Validation-1 cohort

(n = 64)

Validation-2 cohort

(n = 95)

Sex

 

Female

135/308 (43.8%)

75/149 (50.3%)

23/64 (35.9%)

37/95 (38.9%)

Male

173/308 (56.2%)

74/149 (49.7%)

41/64 (64.1%)

58/95 (61.1%)

Age at diagnosis (years)

 

Mean + /– SD

59.4 + /− 19.3

63.4 + /− 18.4

53.5 + /− 21.1

57.2 + /− 18.2

Median [Q1–Q3] (range)

61 [46.5–76] (14–94)

67 [52–79] (16–94)

52.5 [37.5–75] (14–90)

58 [44.5–72] (17–92)

Tumor size (mm)

 

Mean + /- SD

92.4 + /− 52.5

96.1 + /− 57

96 + /− 52.4

84 + /− 44

Median [Q1–Q3] (range)

80 [50–120] (10–310)

80 [60–120] (20–310)

82.5 [57.5–130] (13–275)

80 [50–115] (10–230)

Tumor location

 

Lower limb

185/308 (60.1%)

93/149 (62.4%)

40/64 (62.5%)

52/95 (54.7%)

Trunk wall

82/308 (26.6%)

43/149 (28.9%)

13/64 (20.3%)

26/95 (27.4%)

Upper limb

41/308 (13.3%)

13/149 (8.7%)

11/64 (17.2%)

17/95 (17.9%)

Tumor depth

 

Superficial

36/308 (11.7%)

17/149 (11.4%)

4/64 (6.2%)

15/95 (15.8%)

Deep

206/308 (66.9%)

97/149 (65.1%)

44/64 (68.8%)

65/95 (68.4%)

Superficial and deep

66/308 (21.4%)

35/149 (23.5%)

16/64 (25%)

15/95 (15.8%)

Histologic type§

 

Undifferentiated sarcoma

86/308 (27.9%)

42/149 (28.2%)

9/64 (14.1%)

35/95 (36.8%)

Myxofibrosarcoma

31/308 (10.1%)

19/149 (12.8%)

7/64 (10.9%)

5/95 (5.3%)

Leiomyosarcoma

47/308 (15.3%)

18/149 (12.1%)

9/64 (14.1%)

19/95 (20%)

Myxoid/round cell liposarcoma

33/308 (10.7%)

19/149 (12.8%)

8/64 (12.5%)

6/95 (6.3%)

Dedifferentiated liposarcoma

38/308 (12.3%)

17/149 (11.4%)

11/64 (17.2%)

11/95 (11.6%)

Other sarcoma

67/308 (23.7%)

34/149 (22.8%)

20/64 (31.2%)

13/95 (13.7%)

MPNST

9/308 (2.9%)

3/149 (2%)

1/64 (1.6%)

5/95 (5.3%)

Synovial sarcoma

13/308 (4.2%)

5/149 (3.4%)

6/64 (9.4%)

2/95 (2.1%)

Vascular sarcoma

2/308 (0.6%)

2/149 (1.3%)

0/64 (0%)

0/95 (0%)

Other sarcoma

43/308 (14%)

24/149 (16.1%)

13/64 (20.3%)

6/95 (6.3%)

FNCLCC grade

 

I

47/308 (15.3%)

25/149 (16.8%)

13/64 (20.3%)

9/95 (9.5%)

II

112/308 (36.4%)

54/149 (36.2%)

24/64 (37.5%)

34/95 (35.8%)

III

149/308 (48.4%)

70/149 (47%)

27/64 (42.2%)

52/95 (54.7%)

Surgical margins

 

R0

188/306 (61.4%)

83/149 (55.7%)

33/64 (51.6%)

72/93 (77.4%)

R1

118/306 (38.6%)

66/149 (44.3%)

31/64 (48.4%)

21/93 (22.6%)

Adjuvant chemotherapy

 

No

263/308 (85.4%)

124/149 (83.2%)

52/64 (81.2%)

87/95 (91.6%)

Yes

45/308 (14.6%)

25/149 (16.8%)

12/64 (18.8%)

8/95 (8.4%)

Adjuvant radiotherapy

 

No

77/308 (25%)

35/149 (23.5%)

11/64 (17.2%)

31/95 (32.6%)

Yes

231/308 (75%)

114/149 (76.5%)

53/64 (82.8%)

64/95 (67.4%)

  1. FNCLCC French federation of cancer centers, MPNST malignant peripheral nerve sheath tumor, Q quartile, SD standard deviation.
  2. § Histological type are categorized according to the grouping of the Sarculator nomogram. In details, dedifferentiated liposarcoma corresponds to pleomorphic and dedifferentiated liposarcoma.
  3. Undifferentiated sarcoma corresponds to undifferentiated pleomorphic sarcoma, undifferentiated round cell sarcoma, undifferentiated sarcoma (not otherwise specified) and undifferentiated spindle cell sarcoma.
  4. Vascular sarcoma corresponds to epitheloid hemangioendothelioma and angiosarcoma.
  5. Other sarcoma corresponds to synovial sarcoma, alveolar soft part sarcoma, clear cell sarcoma, soft-tissue dedifferentiated chondrosarcoma, epitheloid sarcoma, extraskeletal myxoid chondrosarcoma, high risk solitary fibrous tumors, low grade fibromyxoid sarcoma, malignant rhabdoid tumor, malignant tenosynovial giant cell tumor, and fibrosarcoma.
Back to article page